Sort

Search

01/12/2022 Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
Pagonabarraga, J, Perez-Gonzalez, R, Bejr-kasem, H, Marin-Lahoz, J, Horta-Barba, A, Martinez-Horta, S, Aracil-Bolanos, I, Sampedro, F, Campolongo, A, Rivas, E, Puig-Davi, A, Ruiz-Barrios, I, Perez-Perez, J, Pascual-Sedano, B, Kulisevsky, J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. PARKINSONISM & RELATED DISORDERS. 2022; 105DOI:10.1016/j.parkreldis.2022.05.020. PMID:35752549. IF:4.100(Q2/3D).
01/12/2022 Trial of Deferiprone in Parkinson's Disease
Devos, D, Labreuche, J, Rascol, O, Corvol, JC, Duhamel, A, Delannoy, PG, Poewe, W, Compta, Y, Pavese, N, Ruzicka, E, Dusek, P, Post, B, Bloem, BR, Berg, D, Maetzler, W, Otto, M, Habert, MO, Lehericy, S, Ferreira, J, Dodel, R, Tranchant, C, Eusebio, A, Thobois, S, Marques, AR, Meissner, WG, Ory-Magne, F, Walter, U, de Bie, RMA, Gago, M, Vilas, D, Kulisevsky, J, Januario, C, Coelho, MVS, Behnke, S, Worth, P, Seppi, K, Ouk, T, Potey, C, Leclercq, C, Viard, R, Kuchcinski, G, Lopes, R, Pruvo, JP, Pigny, P, Garcon, G, Simonin, O, Carpentier, J, Rolland, AS, Nyholm, D, Scherfler, C, Mangin, JF, Chupin, M, Bordet, R, Dexter, DT, Fradette, C, Spino, M, Tricta, F, Ayton, S, Bush, AI, Devedjian, JC, Duce, JA, Cabantchik, I, Defebvre, L, Deplanque, D, Moreau, C. Trial of Deferiprone in Parkinson's Disease. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(22)DOI:10.1056/NEJMoa2209254. PMID:36449420. IF:158.500(Q1/1D).
01/12/2022 New Treatment for the Cognitive and Emotional Deficits Linked with Paclitaxel-Induced Peripheral Neuropathy in Mice
Martinez-Martel, I, Bai, X, Batalle, G, Pol, O. New Treatment for the Cognitive and Emotional Deficits Linked with Paclitaxel-Induced Peripheral Neuropathy in Mice. Antioxidants. 2022; 11(12)DOI:10.3390/antiox11122387. PMID:36552595. IF:7.000(Q1/1D).
01/12/2022 Is Metacognitive Training effective for improving neurocognitive function in patients with a recent onset of psychosis?
Ruiz-Delgado, I, Moreno-Kuestner, B, Garcia-Medina, M, Barrigon, ML, Gonzalez-Higueras, F, Lopez-Carrilero, R, Barrios-Mellado, I, Barajas, A, Pousa, E, Lorente-Rovira, E, Grasa, E, Cid, J, Barrau-Sastre, P, Moritz, S, Ochoa, S, Spanish Metacognition Group. Is Metacognitive Training effective for improving neurocognitive function in patients with a recent onset of psychosis?. PSYCHIATRY RESEARCH. 2022; 318DOI:10.1016/j.psychres.2022.114941. PMID:36375331. IF:11.300(Q1/1D).
01/12/2022 Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group
Baumer, NT, Becker, ML, Capone, GT, Egan, K, Fortea, J, Handen, BL, Head, E, Hendrix, JE, Litovsky, RY, Strydom, A, Tapia, IE, Rafii, MS. Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. Journal of Neurodevelopmental Disorders. 2022; 14(1)DOI:10.1186/s11689-022-09435-z. PMID:35321660. IF:4.900(Q1/3D).
01/12/2022 Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease
Holstege, H, Hulsman, M, Charbonnier, C, Grenier-Boley, B, Quenez, O, Grozeva, D, van Rooij, JGJ, Sims, R, Ahmad, S, Amin, N, Norsworthy, PJ, Dols-Icardo, O, Hummerich, H, Kawalia, A, Amouyel, P, Beecham, GW, Berr, C, Bis, JC, Boland, A, Bossu, P, Bouwman, F, Bras, J, Campion, D, Cochran, JN, Daniele, A, Dartigues, JF, Debette, S, Deleuze, JF, Denning, N, DeStefano, AL, Farrer, LA, Fernandez, MV, Fox, NC, Galimberti, D, Genin, E, Gille, JJP, Le Guen, Y, Guerreiro, R, Haines, JL, Holmes, C, Ikram, MA, Ikram, MK, Jansen, IE, Kraaij, R, Lathrop, M, Lemstra, AW, Lleo, A, Luckcuck, L, Mannens, MMAM, Marshall, R, Martin, ER, Masullo, C, Mayeux, R, Mecocci, P, Meggy, A, Mol, MO, Morgan, K, Myers, RM, Nacmias, B, Naj, AC, Napolioni, V, Pasquier, F, Pastor, P, Pericak-Vance, MA, Raybould, R, Redon, R, Reinders, MJT, Richard, AC, Riedel-Heller, SG, Rivadeneira, F, Rousseau, S, Ryan, NS, Saad, S, Sanchez-Juan, P, Schellenberg, GD, Scheltens, P, Schott, JM, Seripa, D, Seshadri, S, Sie, D, Sistermans, EA, Sorbi, S, van Spaendonk, R, Spalletta, G, Tesi, N, Tijms, B, Uitterlinden, AG, van der Lee, SJ, Visser, PJ, Wagner, M, Wallon, D, Wang, LS, Zarea, A, Clarimon, J, van Swieten, JC, Greicius, MD, Yokoyama, JS, Cruchaga, C, Hardy, J, Ramirez, A, Mead, S, van der Flier, WM, van Duijn, CM, Williams, J, Nicolas, G, Bellenguez, C, Lambert, JC. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. NATURE GENETICS. 2022; 54(12)DOI:10.1038/s41588-022-01208-7. PMID:36411364. IF:30.800(Q1/1D).